Fisher Asset Management LLC Buys 23,103 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Fisher Asset Management LLC boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 518,027 shares of the company's stock after acquiring an additional 23,103 shares during the quarter. Fisher Asset Management LLC owned 0.65% of Viridian Therapeutics worth $9,931,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VRDN. International Assets Investment Management LLC bought a new position in Viridian Therapeutics in the 3rd quarter valued at about $455,000. AlphaCentric Advisors LLC lifted its position in Viridian Therapeutics by 20.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock valued at $341,000 after acquiring an additional 2,500 shares in the last quarter. Principal Financial Group Inc. increased its stake in Viridian Therapeutics by 1,603.4% in the 3rd quarter. Principal Financial Group Inc. now owns 172,810 shares of the company's stock valued at $3,931,000 after buying an additional 162,665 shares during the last quarter. Mesirow Financial Investment Management Inc. purchased a new stake in Viridian Therapeutics in the 3rd quarter valued at about $372,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Viridian Therapeutics in the 3rd quarter valued at about $208,000.

Viridian Therapeutics Stock Performance

VRDN traded up $0.06 on Friday, hitting $15.94. The company's stock had a trading volume of 1,008,783 shares, compared to its average volume of 1,182,109. The company's 50 day simple moving average is $17.86 and its 200-day simple moving average is $19.64. The firm has a market cap of $1.26 billion, a P/E ratio of -3.70 and a beta of 1.05. Viridian Therapeutics, Inc. has a 12 month low of $11.40 and a 12 month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Remove Ads

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on VRDN. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. TD Cowen began coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating for the company. Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Viridian Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.